All GLG News Analyses Filed Under: Endocrinology

One more drug for DM2 treatment.

Galvus receives European approval, but has significant barriers for prescribing. This places Galvus significantly behind Januvia as a diabetes treatment option

After the many false hopes raised using surrogate markers, we certainly want to wait for definitive end-point trial results involving fracture rate and possible long-term side effects.  However the 40% greater increase in BMD compared to the standard of bisphosphonate therapy is quite exciting. ...

The marker of comparison should be less fractures not BMD changes. What are the long term effects of using such a monclonal antibody and what will be  its cost?

Impressive data on Ranexa in HGBA1c. The result of a decrease of 0.64 vs baseline and 0.43 vs placebo are at first glance underwhelming.  But a closer looks shows that the results are realy quite impressive

My expertise in the clinical research of Torcetrapib and reports presented at the latest American College of Cardiology meetings made me conclude that the failure of  Torcetrapib in rendering clinical benefits were related to intrinsic problems of the drug which effected the nature of the HDL which...

Those like myself who have more extensive knowledge on the rational used by the FDA to reject the approval of Rimonabant and know the differences between Rimonabant and Taranabant do not believe that there is an error in judgment by Merck in developing their new cannabinoid receptor antagonist. This...

Considering the guidance that having diabetes is a cardiovascular risk factor equivalent to having a previous CV event, the practice of adding a statin to the diabetic's medication regime is already widely practiced. Since the ADA guidelines are LDL goal < 100, or goal <70 with risk...

Diabesity is pandemic, too late diagnosed, too little treated.  ADA recommendations for screening with fasting blood sugars result in relatively late diagnoses since the FBS doesn't usually rise until the disease has been present for several years. 

This should not surprise anyone in the field. Diabetes is a risk equivalent to having a previous MI. This data has been available for awhile. Good practice should dictate that all diabetics be on a statin + .